137 related articles for article (PubMed ID: 28382859)
21. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.
Vogel RI; Pulver T; Heilmann W; Mooneyham A; Mullany S; Zhao X; Shahi M; Richter J; Klein M; Chen L; Ding R; Konecny G; Kommoss S; Winterhoff B; Ghebre R; Bazzaro M
Oncotarget; 2016 May; 7(21):30962-76. PubMed ID: 27121063
[TBL] [Abstract][Full Text] [Related]
22. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.
Angioli R; Capriglione S; Scaletta G; Aloisi A; Miranda A; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2016 Apr; 37(4):4973-8. PubMed ID: 26531723
[TBL] [Abstract][Full Text] [Related]
23. Endometrial cancer: A systematic review of HE4, REM and REM-B.
Degez M; Caillon H; Chauviré-Drouard A; Leroy M; Lair D; Winer N; Thubert T; Dochez V
Clin Chim Acta; 2021 Apr; 515():27-36. PubMed ID: 33388311
[TBL] [Abstract][Full Text] [Related]
24. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study.
Fanfani F; Restaino S; Cicogna S; Petrillo M; Montico M; Perrone E; Radillo O; De Leo R; Ceccarello M; Scambia G; Ricci G
Int J Gynecol Cancer; 2017 Jul; 27(6):1200-1205. PubMed ID: 28557834
[TBL] [Abstract][Full Text] [Related]
26. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
27. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and survival rates for endometrial carcinoma.
Zhang Y; Qu X; Qu PP
J BUON; 2016; 21(6):1491-1495. PubMed ID: 28039713
[TBL] [Abstract][Full Text] [Related]
28. The role of HE4 in differentiating benign and malignant endometrial pathology.
Gąsiorowska E; Magnowska M; Iżycka N; Warchoł W; Nowak-Markwitz E
Ginekol Pol; 2016; 87(4):260-4. PubMed ID: 27321096
[TBL] [Abstract][Full Text] [Related]
29. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4.
Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
[TBL] [Abstract][Full Text] [Related]
30. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
31. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.
Bie Y; Zhang Z
World J Surg Oncol; 2014 May; 12():169. PubMed ID: 24885319
[TBL] [Abstract][Full Text] [Related]
33. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
[TBL] [Abstract][Full Text] [Related]
34. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
35. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.
Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F
Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710
[TBL] [Abstract][Full Text] [Related]
37. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
[TBL] [Abstract][Full Text] [Related]
38. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
39. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.
James NE; Emerson JB; Borgstadt AD; Beffa L; Oliver MT; Hovanesian V; Urh A; Singh RK; Rowswell-Turner R; DiSilvestro PA; Ou J; Moore RG; Ribeiro JR
Sci Rep; 2020 May; 10(1):8558. PubMed ID: 32444701
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of galectin-7 in epithelial ovarian cancer.
Kim HJ; Jeon HK; Lee JK; Sung CO; Do IG; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Anticancer Res; 2013 Apr; 33(4):1555-61. PubMed ID: 23564797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
